![Page 1: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/1.jpg)
Influenza Outbreaks
An Overview for Pharmacists Prescribing Antiviral Medications
Under the Collaborative Drug Therapy Agreement for Influenza Antiviral Medications
![Page 2: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/2.jpg)
2
Learning Objectives
1. Understand the pharmacist’s role in an outbreak
2. Understand the characteristics of an influenza outbreak
3. Identify influenza illness & cases needing referral
4. Prescribe antiviral medications for treatment and prophylaxis
5. Advise proper self-care & preventive measures
![Page 3: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/3.jpg)
3
1. Your Role as a Pharmacist in the Public Health Response
Under this Collaborative Drug Therapy Agreement (CDTA)
![Page 4: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/4.jpg)
4
Collaborative Drug Therapy AgreementPharmacist’s Role
Pharmacists in the State of Washington may prescribe antivirals under a CDTA with a licensed, authorized prescriber
• CDTA template for Influenza Antiviral Medications developed in 2009
• To be activated by Local Health Officer
• CDTA covers prescribing of antiviral medications for influenza
![Page 5: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/5.jpg)
5
Organization of ResponsePharmacist’s Role
Agency RoleCenters for Disease Control (CDC)
•Monitors the outbreak and provides updated guidance and new information
•Manages Strategic National Stockpile (SNS) of antiviral medications
Washington State Department of Health (DOH)
• Requests, manages and distributes SNS medications for the state
Local Health Office •Distributes SNS medications to pharmacies
•Authorizes their use for treatment and/or prophylaxis
Pharmacists •Prescribe and dispense antiviral medications under this CDTA
![Page 6: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/6.jpg)
6
Requirements to Prescribe
Pharmacists should:
1. View this training presentation2. Pass the self-assessment quiz3. Review the protocol4. Review information in tool kit
• Prescribing and dispensing must be documented, reported and reviewable
• Interns may participate if they are working under direct pharmacist supervision
Pharmacist’s Role
![Page 7: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/7.jpg)
7
2. Characteristics of an Influenza Outbreak
![Page 8: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/8.jpg)
8
Influenza A (H1N1)
• Novel strain of influenza (swine flu)
• Risk groups same as seasonal flu, except elderly are less susceptible, pregnant women and children are more
• Vaccine available October 2009
Characteristics of the Influenza Outbreak
![Page 9: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/9.jpg)
9
How does the influenza virus spread?
Infectious period:
Characteristics of the Influenza Outbreak
• 1 day prior to symptom onset up to
7 days after onset of symptoms
• Spread via inhalation of infected droplets
![Page 10: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/10.jpg)
10
3. Identify Influenza Illness & Cases Needing Referral
![Page 11: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/11.jpg)
11
Identifying Influenza: Signs & Symptoms
• Fever (> 100° F )• Cough• Sore throat• Arthralgia/myalgia • Headache• Chills
Influenza Cases & Referral Cases
• Fatigue• Anorexia• Rhinorrhea• Nausea • Vomiting• Diarrhea
![Page 12: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/12.jpg)
12
Screening Form TemplateInfluenza Cases & Referral Cases
• Decision-making tool
• Required for documentation
of antiviral medications prescribed
![Page 13: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/13.jpg)
13
High Risk Patients
• Elderly are less susceptible, but may develop more severe illness
• Pregnant women and children are more susceptible and may develop more severe illness
• May be managed in the pharmacy
• Local Health Officer may recommended for preferential treatment or prophylaxis
Influenza Cases & Referral Cases
![Page 14: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/14.jpg)
14
Identifying High Risk Patients
• Less than 5 years old
• Over 65 years old
• Chronic medical conditions
• Immunosuppressed
• Pregnant women
• Persons less than 18 years old receiving long-term aspirin therapy
• Residents of nursing homes and chronic-care facilities
Influenza Cases & Referral Cases
![Page 15: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/15.jpg)
15
When to Refer?
• Symptoms of pneumonia
• High or persistent fever (>48 hours)
• Central nervous system symptoms• Neck Pain• Mental Status Changes
Influenza Cases & Referral Cases
![Page 16: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/16.jpg)
16
PneumoniaInfluenza Cases & Referral Cases
Pneumonia is the leading complication and cause of death during an influenza outbreak.
Symptoms include
Cough, high fever, pleuritic chest pain, dyspnea, rigors, chills, sputum and cyanosis, chills, sputum and cyanosis
![Page 17: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/17.jpg)
17
Adult Emergency Warning Signs
• Difficulty breathing or shortness of breath • Pain or pressure in the chest or abdomen • Sudden dizziness • Confusion • Severe or persistent vomiting • Flu-like symptoms improve but then return with
fever and worse cough
![Page 18: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/18.jpg)
18
Child Emergency Warning Signs
• Fast breathing or trouble breathing • Bluish or gray skin color (call 911 immediately)• Not drinking enough fluids • Severe or persistent vomiting • Not waking up or not interacting • Being so irritable that the child does not want to be
held • Flu-like symptoms improve but then return with
fever and worse cough
![Page 19: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/19.jpg)
19
Referral Based on TemperatureInfluenza Cases & Referral Cases
Refer when temperatures exceed the following for over 48 hours:
100.5°F < 1 yr. old
101° F 1-17 yrs. old
102° F > 17 yrs. old
![Page 20: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/20.jpg)
20
Referral Steps
1. Prescribe and dispense antiviral medications in accordance with the CDTA Protocol for Influenza Antiviral Medications
2. Advise patient to seek care from:1. Primary care provider2. Emergency department3. Urgent care center
Influenza Cases & Referral Cases
![Page 21: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/21.jpg)
21
Why Take a Temperature?
• Identify people who do NOT need treatment
• Identify people who are severely ill, need referral
Influenza Cases & Referral Cases
![Page 22: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/22.jpg)
22
4. Prescribing Antiviral Medications for Treatment
and Prophylaxis of Influenza
![Page 23: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/23.jpg)
23
Antiviral Medications
Novel Influenza A (H1N1) virus is resistant to adamantanes, but sensitive to neuraminidase inhibitors
Neuraminidase inhibitors: oseltamivirzanamivir
Adamantanes: amantadinerimantadine
Prescribing Antiviral Medications
![Page 24: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/24.jpg)
24
Antiviral Medications
Novel Influenza A (H1N1) virus is resistant to adamantanes, but sensitive to neuraminidase inhibitors
Neuraminidase inhibitors: oseltamivirzanamivir
Adamantanes: amantadinerimantadine
Prescribing Antiviral Medications
X
![Page 25: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/25.jpg)
25
Mechanisms of ActionPrescribing Antiviral Medications
![Page 26: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/26.jpg)
26
Neuraminidase Inhibitors
Treatment & prevention of influenza A & B:
Oseltamivir (Tamiflu®)• Individuals 1 year old or older
Zanamivir (Relenza®)• Treatment of individuals ≥ 7 years of age • Prevention in individuals ≥ 5 years of age
• Not recommended for persons with underlying airway disease
Prescribing Antiviral Medications
![Page 27: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/27.jpg)
27
Recommended Durations
Treatment• Start ASAP within 2 days of onset of symptoms • Continue for 5 days
Prophylaxis – only when directed by Local Health OfficerPost-exposure: • Start ASAP after last known exposure• Continue for 10 days Pre-exposure: • Start during potential exposure period• Continue for 10 days after last known exposure
Prescribing Antiviral Medications
![Page 28: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/28.jpg)
28
Oseltamivir Dosing for Treatment or Prophylaxis
Prescribing Antiviral Medications
Oseltamivir Treatment - for 5 days Prophylaxis – for 10 days
Adults 75 mg capsule twice daily 75 mg capsule once daily
Children (age ≥ 12 months), Weight ≤ 15 kg
60 mg per day divided into 2 doses 30 mg once per day
15-23 kg 90 mg per day divided into 2 doses 45 mg once per day
24-40 kg 120 mg per day divided into 2 doses 60 mg once per day
>40 kg 150 mg per day divided into 2 doses 75 mg once per day
Reduce the dose for adults with renal impairment, CrCl 10-30 mL/min:Treatment: 75 mg once daily for 5 daysProphylaxis: 75 mg every other day or 30 mg once daily
![Page 29: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/29.jpg)
29
Oseltamivir Use Under an Emergency Use Authorization (EUA)
• Infants
• Have high rates of morbidity and mortality from influenza
• Use for children less than 1 year old recently approved by the U.S. FDA under an EUA
• Limited data exist on safety and dosing
• Carefully monitor infants for adverse events
• Treatment timeframe increased to include those with > 48 hours of symptoms
Prescribing Antiviral Medications
![Page 30: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/30.jpg)
30
Oseltamivir Use Under an EUA
Treatment of children younger than 1 year
Age Recommended treatment dose for 5 days
< 3 months 12 mg twice daily
3-5 months 20 mg twice daily
6-11 months 25 mg twice daily
Prescribing Antiviral Medications
Prophylaxis of children younger than 1 yearAge Recommended treatment dose for 5 days
< 3 months Not recommended unless situation judged critical due to limited data on use in this age group
3-5 months 20 mg once daily
6-11 months 25 mg once daily
![Page 31: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/31.jpg)
31
Zanamivir Dosing for Treatment or Prophylaxis
Prescribing Antiviral Medications
Zanamivir Treatment - for 5 days Prophylaxis – for 10 daysAdults Two 5 mg inhalations (10 mg
total) twice per dayTwo 5 mg inhalations (10 mg total) once per day
Children Two 5 mg inhalations (10 mg total) twice per day (age ≥ 7 years)
Two 5 mg inhalations (10 mg total) once per day (age ≥ 5 years)
Under EUA, zanamivir may also be used to treat patients who have had symptoms for >48 hours.
![Page 32: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/32.jpg)
32
Pregnant Women
Pregnancy should NOT be considered a contraindication to treat
• Despite the fact that they are Pregnancy Category C – to be used during pregnancy ONLY if the potential benefit justifies the potential risk to the embryo or fetus
• Experts prefer zanamivir over oseltamivir for pregnant women
• No relation between these medications and adverse reproductive outcomes have been established
Prescribing Antiviral Medications
![Page 33: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/33.jpg)
33
Breastfeeding Considerations
• Women with influenza should continue breastfeeding and increase feeding frequency
• Antiviral medication treatment or prophylaxis is not a contraindication for breastfeeding
Prescribing Antiviral Medications
![Page 34: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/34.jpg)
34
Adverse Event Reporting
In case of severe medication side effects pharmacists should:
• Stop antiviral therapy• Recommend OTC treatment for side effect
management• If severe, refer for medical evaluation• Record and report suspected medication side effect
information to MedWatch:
1-800-FDA-1088https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm
Prescribing Antiviral Medications
![Page 35: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/35.jpg)
35
5. Patient Information
![Page 36: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/36.jpg)
36
Oseltamivir (Tamiflu®)
Common Adverse Drug Reactions: • Nausea/vomiting • Abdominal pain
Counseling tips:• Stay hydrated• Eat small frequent meals to help with possible
nausea/vomiting • Use sugar-free candy or sugar-free gum to help with
nausea/vomiting
Patient Information
![Page 37: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/37.jpg)
37
Zanamivir (Relenza®)
Potential Adverse Drug Reactions: • Headache, dizziness, nausea/vomiting, muscle pain,
diarrhea, cough, nasal and throat irritation
Counseling tips: • Drink non-caffeinated liquid• Eat small frequent meals to help with
nausea/vomiting • Use hard sugar-free candy or sugar-free gum to help
with nausea/vomiting• Start treatment immediately, if possible take 2 doses
on first day separated by at least 2 hours• Demonstrate correct use of inhaler device
Patient Information
![Page 38: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/38.jpg)
38
How-to-Use Relenza® Inhaler
Click here for Video
Patient Information
![Page 39: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/39.jpg)
39
Other Medications
OTC medications for
symptomatic treatment
• Acetaminophen
• Ibuprofen
• Naproxen
Patient Information
![Page 40: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/40.jpg)
40
Non-Pharmacologic Interventions
• Limit close contact
• Wash hands with soap or use alcohol-based sanitizer
• Drink clear fluids
• Cover mouth when coughing or sneezing
• Stay at home at least 7 days after illness began and 24 hours after fever has abated
Patient Information
![Page 41: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/41.jpg)
41
Resources
• U.S. Centers for Disease Control and Prevention www.cdc.gov
• Washington State Pharmacy Association http://wsparx.org/
• Washington State Board of Pharmacy http://www.doh.wa.gov/hsqa/professions/pharmacy/default.htm
• WA State Department of Health – link to your local public health office
www.doh.wa.gov
Pharmacist’s Role
Photography used throughout this presentation is from the CDC’s Public Health Image Library.
![Page 42: Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral](https://reader037.vdocuments.us/reader037/viewer/2022110400/56649db25503460f94aa1376/html5/thumbnails/42.jpg)
42
Acknowledgements
Contributors:
Jenny Arnold, Pharm.D.Rebecca Bartlein, MPHcVeena Karir, Pharm.D.Jeff Rochon, Pharm.D. Andy Stergachis, Ph.D., R.Ph.Dean Webb, R.Ph., M.S.
Advisors:
Jeffrey Duchin, M.D., FACP, FIDSA
Tim Fuller R.Ph., M.S., FASHP
Jim Gale, M.D., MPH
Michael Loehr, MPA
Dave Owens
Colleen Terriff, Pharm.D., BCPS (AQ-ID)